When Rosana Kapeller was working at Nimbus Therapeutics in the early 2010s the technology to study the socalled dark genome didn't exist. Fourteen years later Kapeller is running a biotechnology startup well on its way to shedding light on how those lessexplored stretches of DNA could yield new drugs